DR STUART ALLEN JONES
` _________________________________________________________
`Reader - Pharmaceutics, Pharmacy Dept.,
`CURRENT
`2019 – present
`POST(S)
`King’s College London, UK
`
`PREVIOUS
`APPOINTMENTS
`
`EDUCATION
`
`RESEARCH
`FUNDING
`
`Senior Lecturer – Pharmaceutics, Pharmacy
`Dept. King’s College London
`Consultant Pharmacist, Directorate of
`Rational Use of Medicines, Ministry of Health,
`Oman (12 month secondment)
`Company Founder, Porto Life Sciences,
`Oxford, UK (part-time post).
`Lecturer - Pharmaceutics, Pharmacy Dept.,
`King’s College London, UK
`Pharmaceutical Consultant, King’s College
`London
`Pharmaceutical Consultant, MedPharm Ltd,
`Guildford, UK
`Head of Research and Development,
`MedPharm Ltd, UK
`Formulation Scientist
`Pfizer Pharmaceuticals, UK
`
`PhD Drug Delivery
`Pharmacy Dept., King’s College London, UK
`Masters Degree in Academic Practice
`King’s Learning Institute, King’s College
`London, UK
`Masters Degree in Pharmacy
`University of Nottingham, UK
`Diploma Academic Practice
`King’s Learning Institute, UK
`
`Post-Doc Grant ‘Engineering a topical
`hypobaric patch: A needle-free solution for
`biopharmaceutical drug administration into
`the skin’
`(EPSRC) S. A. Jones
`Research Assistant Grant. Phosphorylated
`vitamins and oral health
`(GSK Ltd) S. A. Jones and G. Carpenter
`Post-Doc Grant’ Vasodilator nitric oxide
`donors’
`(Syndermix Ltd.) S. A. Jones, S. Brain
`Hypobaric cytokine profiling a noninvasive
`means to characterise skin health during
`aging
`RoseTrees Trust
`Multifunctional self-assembling ion-pair
`complexes
`(EPSRC, Johnson and Johnson Ltd, UK) S. A.
`Jones
`The influence of barometric pressure
`changes upon membrane physiology and
`
`2010 - 2019
`
`2015 – 2016
`
`2008 – 2012
`
`2005 –2010
`
`2009 - present
`
`2005 – 2009
`
`2004 –2005
`
`2001- 2002
`
`2002 –2005
`
`2013 – 2015
`
`1997 –2001
`
`2011 –2013
`
`2019-2022
`£568,560
`
`2019-2020
`£28,000
`
`2018-2019
`£65,000
`
`2017-2020
`£60,000
`
`2013-2017
`£112,630
`
`2013- 2017
`£90,000
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 1
`
`

`

`xenobiotic penetration
`(BBSRC, UK) S. A. Jones
`In vitro biopharmaceutical evaluation of
`novel respiratory medicines for airway
`disease
`(MRC, GlaxoSmithKline Ltd, UK) S. A. Jones,
`B. Forbes, C. Page
`The formation and delivery of novel drug-
`ion-pair combinations to the airways of the
`lung
`(EPSRC, MedPharm Ltd, UK) S. A. Jones, C.
`Page
`In Vivo Safety and Particokinetics of Inhaled
`Nanomedicines
`(MRC, UK) S. A. Jones, B. Forbes, L. Daily, D.
`Spina. C. Page
`Mucus penetrating nanoparticles – a novel
`targeting strategy for the treatment of
`respiratory disease
`(BBSRC, UK) S. A. Jones
`Novel cosmetically acceptable methods of
`keratin manipulation to facilitate hair
`removal
`(EPSRC and DTI, UK) S. A. Jones
`A fundamental investigation of the barrier
`properties of the human nail
`(BBSRC, UK) S. A. Jones, M. B. Brown, M.
`Traynor, S. Murdan
`Development of a novel self-assembling
`thermoregulation device to enhance
`transdermal drug delivery’
`(EPSRC and MedPharm) S. A. Jones
`A novel intransal microencapsulated
`nanoparticle formulation
`(BBSRC SBRI and MedPharm Ltd) S. A.
`Jones, M. B. Brown,
`The development of a novel self-assembling
`patchless-patch (Medspray) for topical drug
`delivery
`(SEEDA) S. A. Jones M. B. Brown.
`Engineering of novel nanofoams
`(BBSRC Dorothy Hodgkin award)
`S. A. Jones
`‘Novel topical formulations for ungula drug
`delivery’
`(BBSRC SBRI with MedPharm)
`Iontophoresis induced collagen production
`(Transport Pharmaceuticals) S. A. Jones, M. B.
`Brown.
`Novel topical formulations for ungula drug
`delivery
`(MedPharm Ltd studentship) S. A. Jones, M. B.
`Brown.
`
`2011- 2015
`£90,000
`
`2009-2013
`£90,000
`
`2010-2013
`£660, 000
`
`2009-2013
`£70,000
`
`2010- 2012
`£121,600
`
`2010-2012
`£280,000
`
`2006-2010
`£70,000
`
`2006-2008
`£203,000
`
`2005-2009
`£230,000
`
`2005-2009
`£75,000
`
`£215,000
`2005-2007
`
`2005-2009
`£110,000
`
`2005-2008
`£67,000
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 2
`
`

`

`RESEARCH
`PUBLICATIONS
`
`H-index (19
`Scopus)
`
`Harper, R. A., Petersen, L., Saleh, M.M., Proctor, G. B., Carpenter, G.
`H., Gambogi, R., Hider, R., Jones, S.A. Targeting macrophages and
`their recruitment in the oral cavity using swellable (+) alpha
`tocopheryl phosphate nanostructures, Nanomedicine:
`Nanotechnology, Biology and Medicine. (2019) 21: 102010
`
`Chen, H. Mansfield, E.D.H., Woods, A., Khutoryanskiy, V.V.,
`Forbes, B., Jones, S.A. Mucus penetrating properties of soft,
`distensible lipid nanocapsules European Journal of Pharmaceutics
`and Biopharmaceutics. (2019) 139, pp 76-84.
`
`Harper, R.A., Saleh, M.M., Carpenter, G., Abbate, V., Proctor, G.,
`Harvey, R.D., Gambogi, R.J., Geonnotti, A., Hider, R., Jones, S.A.
`Diminishing biofilm resistance to antimicrobial nanomaterials through
`electrolyte screening of electrostatic interactions Colloids and
`Surfaces B: Biointerfaces. (2019) 173 (1), pp 392-399.
`
`Benaouda, F., Jones, S.A., Chana, J., Dal Corno, B.M., Barlow, D.J.,
`Hider, R.C., Page, C.P., Forbes, B. Ion-Pairing with Spermine Targets
`Theophylline to the Lungs via the Polyamine Transport System
`(2018) Molecular Pharmaceutics, 15 (3), pp. 861-870.
`
`Harper, R.A., Saleh, M.M., Carpenter, G., Abbate, V., Proctor, G.,
`Harvey, R.D., Gambogi, R.J., Geonnotti, A., Hider, R., Jones, S.A.
`Soft, adhesive (+) alpha tocopherol phosphate planar bilayers that
`control oral biofilm growth through a substantive antimicrobial effect
`(2018) Nanomedicine: Nanotechnology, Biology, and Medicine, .
`Article in Press.
`
`Cai, X.J., Mesquida, P., Jones, S.A. Investigating the ability of
`nanoparticle-loaded hydroxypropyl methylcellulose and xanthan gum
`gels to enhance drug penetration into the skin (2016) International
`Journal of Pharmaceutics, 513 (1-2), pp. 302-308.
`
`Patel, A., Keir, S.D., Brown, M.B., Hider, R., Jones, S.A., Page, C.P.
`Using Salt Counterions to Modify β2-Agonist Behaviour in Vivo
`(2016) Molecular Pharmaceutics, 13 (10), pp. 3439-3448.
`
`Chen, H., Woods, A., Forbes, B., Jones, S. Controlled drug release
`from lung-targeted nanocarriers via chemically mediated shell
`permeabilization (2016) International Journal of Pharmaceutics, 511
`(2), pp. 1033-1041.
`
`Patel, A., Woods, A., Riffo-Vasquez, Y., Babin-Morgan, A., Jones, M.-
`C., Jones, S., Sunassee, K., Clark, S., De Rosales, R.T.M., Page, C.,
`Spina, D., Forbes, B., Dailey, L.A. Lung inflammation does not affect
`the clearance kinetics of lipid nanocapsules following pulmonary
`administration 2016) Journal of Controlled Release, 235, pp. 24-33.
`
`Inacio, R., Barlow, D., Kong, X., Keeble, J., Jones, S.A.
`Investigating how the attributes of self-associated drug complexes
`influence the passive transport of molecules through biological
`membranes (2016) European Journal of Pharmaceutics and
`Biopharmaceutics, 102, pp. 214-222.
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 3
`
`

`

`McAuley, W.J., Jones, S.A., Traynor, M.J., Guesné, S., Murdan, S.,
`Brown, M.B. An investigation of how fungal infection influences drug
`penetration through onychomycosis patient's nail plates (2016)
`European Journal of Pharmaceutics and Biopharmaceutics, 102, pp.
`178-184.
`
`Cai, X.J., Patel, T., Woods, A., Mesquida, P., Jones, S.A.
`Investigating the influence of drug aggregation on the percutaneous
`penetration rate of tetracaine when applying low doses of the agent
`topically to the skin (2016) International Journal of Pharmaceutics,
`502 (1-2), pp. 10-17.
`
`Cai, X.J., Woods, A., Mesquida, P., Jones, S.A. Assessing the
`Potential for Drug-Nanoparticle Surface Interactions to Improve Drug
`Penetration into the Skin (2016) Molecular Pharmaceutics, 13 (4), pp.
`1375-1384.
`
`Inacio, R., Poland, S., Cai, X.J., Cleary, S.J., Ameer-Beg, S., Keeble,
`J., Jones, S.A. The application of local hypobaric pressure - A novel
`means to enhance macromolecule entry into the skin (2016) Journal
`of Controlled Release, 226, pp. 66-76.
`
`Fiala, S., Roman, M., Inacio, R., Mashal, S., Brown, M.B., Jones, S.A.
`New insights into eutectic cream skin penetration enhancement
`(2016) International Journal of Pharmaceutics, 499 (1-2), pp. 403-
`411.
`
`Benaouda, F., Jones, S.A., Martin, G.P., Brown, M.B.
`Localized Epidermal Drug Delivery Induced by Supramolecular
`Solvent Structuring (2016) Molecular Pharmaceutics, 13 (1), pp. 65-
`72.
`
`Dailey, L.A., Hernández-Prieto, R., Casas-Ferreira, A.M., Jones, M.-
`C., Riffo-Vasquez, Y., Rodríguez-Gonzalo, E., Spina, D., Jones, S.A.,
`Smith, N.W., Forbes, B., Page, C., Legido-Quigley, C. Adenosine
`monophosphate is elevated in the bronchoalveolar lavage fluid of
`mice with acute respiratory toxicity induced by nanoparticles with high
`surface hydrophobicity (2015) Nanotoxicology, 9 (1), pp. 106-115.
`
`Jones, S.A., Fiala, S., Brown, M.B. Eutectic systems for penetration
`enhancement (2015) Percutaneous Penetration Enhancers Chemical
`Methods in Penetration Enhancement: Drug Manipulation Strategies
`and Vehicle Effects, pp. 163-173.
`
`Chana, J., Forbes, B., Jones, S.A. Triggered-release nanocapsules
`for drug delivery to the lungs (2015) Nanomedicine: Nanotechnology,
`Biology, and Medicine, 11 (1), pp. 89-97.
`
`Baraldi, A., Jones, S.A., Guesné, S., Traynor, M.J., McAuley, W.J.,
`Brown, M.B., Murdan, S. Human Nail Plate Modifications Induced by
`Onychomycosis: Implications for Topical Therapy (2015)
`Pharmaceutical Research, 32 (5), pp. 1626-1633.
`
`Jones, M.-C., Jones, S.A., Riffo-Vasquez, Y., Spina, D., Hoffman, E.,
`Morgan, A., Patel, A., Page, C., Forbes, B., Dailey, L.A.
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 4
`
`

`

`Quantitative assessment of nanoparticle surface hydrophobicity and
`its influence on pulmonary biocompatibility (2014) Journal of
`Controlled Release, 183 (1), pp. 94-104.
`
`Teixeira, R.S., Veiga, F.J.B., Oliveira, R.S., Jones, S.A., Silva,
`S.M.C., Carvalho, R.A., Valente, A.J.M. Effect of Cyclodextrins and
`pH on the permeation of tetracaine: Supramolecular assemblies and
`release behaviour (2014) International Journal of Pharmaceutics, 466
`(1-2), pp. 349-358.
`
`Baraldi, A., Khengar, R.H., Murdan, S., Traynor, M.J., Jones, S.A.,
`Brown, M.B. The effect of disulphide bond disruption on the barrier
`integrity of the human nail (2014) Issues in Toxicology, pp. 101-112.
`
`Zhao, Y., Alas'Ad, M.A., Jones, S.A. Modifying theophylline
`microparticle surfaces via the sequential deposition of poly(vinyl
`alcohol-co-vinyl acetate) copolymers (2014) International Journal of
`Pharmaceutics, 463 (1), pp. 27-30.
`
`Benaouda, F., Bachoo, Z., Brown, M.B., Martin, G.P., Jones, S.A.
`In situ self assembly of soft diclofenac loaded microparticles in
`superstructured fluids (2013) Soft Matter, 9 (42), pp. 10165-10173.
`
`Reid, M.L., Benaouda, F., Khengar, R., Jones, S.A., Brown, M.B.
`Topical corticosteroid delivery into human skin using
`hydrofluoroalkane metered dose aerosol sprays (2013) International
`Journal of Pharmaceutics, 452 (1-2), pp. 157-165.
`
`Benaouda, F., Brown, M.B., Shah, B., Martin, G.P., Jones, S.A.
`The influence of self-assembling supramolecular structures on the
`passive membrane transport of ion-paired molecules (2012)
`International Journal of Pharmaceutics, 439 (1-2), pp. 334-341.
`
`Benaouda, F., Brown, M.B., Martin, G.P., Jones, S.A.
`Triggered in situ drug supersaturation and hydrophilic matrix self-
`assembly (2012) Pharmaceutical Research, 29 (12), pp. 3434-3442.
`
`Benaouda, F., Brown, M.B., Ganguly, S., Jones, S.A., Martin, G.P.
`Discriminating the molecular identity and function of discrete
`supramolecular structures in topical pharmaceutical formulations
`(2012) Molecular Pharmaceutics, 9 (9), pp. 2505-2512.
`
`Wood, D.G., Brown, M.B., Jones, S.A. Understanding heat facilitated
`drug transport across human epidermis (2012) European Journal of
`Pharmaceutics and Biopharmaceutics, 81 (3), pp. 642-649.
`
`Zhao, Y., Brown, M.B., Khengar, R.H., Traynor, M.J., Barata, P.,
`Jones, S.A. Pharmacokinetic evaluation of intranasally administered
`vinyl polymer-coated lorazepam microparticles in rabbits
`(2012) AAPS Journal, 14 (2), pp. 218-224.
`
`Grainger, C.I., Saunders, M., Buttini, F., Telford, R., Merolla, L.L.,
`Martin, G.P., Jones, S.A., Forbes, B. Critical characteristics for
`corticosteroid solution metered dose inhaler bioequivalence
`(2012) Molecular Pharmaceutics, 9 (3), pp. 563-569.
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 5
`
`

`

`Fiala, S., Brown, M.B., Jones, S.A. Dynamic in-situ eutectic formation
`for topical drug delivery (2011) Journal of Pharmacy and
`Pharmacology, 63 (11), pp. 1428-1436.
`
`Traynor, M.J., Zhao, Y., Brown, M.B., Jones, S.A. Vinyl polymer-
`coated lorazepam particles for drug delivery to the airways (2011)
`International Journal of Pharmaceutics, 410 (1-2), pp. 9-16.
`
`Staff, K., Brown, M.B., Chilcott, R.P., Hider, R.C., Jones, S.A., Kong,
`X.L. Ga(III) complexes-The effect of metal coordination on potential
`systemic absorption after topical exposure (2011) Toxicology Letters,
`202 (3), pp. 155-160.
`
`Wood, D.G., Brown, M.B., Jones, S.A., Murnane, D. Characterization
`of latent heat-releasing phase change materials for dermal therapies
`(2011) Journal of Physical Chemistry C, 115 (16), pp. 8369-8375.
`
`Wood, D.G., Brown, M.B., Jones, S.A. Controlling barrier penetration
`via exothermic iron oxidation (2011) International Journal of
`Pharmaceutics, 404 (1-2), pp. 42-48.
`
`Jones, S.A. Suspension versus solution metered dose inhalers:
`Different products, different particles? (2011) Journal of Drug Delivery
`Science and Technology, 21 (4), pp. 319-322.
`
`Jones, S.A., Kalia, M. Inhaled formulation development: Back to
`basics? (2010) Pharmaceutical Manufacturing and Packing Sourcer,
`(WINTER), pp. 52-56.
`
`Moddaresi, M., Brown, M.B., Zhao, Y., Tamburic, S., Jones, S.A.
`The role of vehicle-nanoparticle interactions in topical drug delivery
`(2010) International Journal of Pharmaceutics, 400 (1-2), pp. 176-
`182.
`
`Khengar, R.H., Brown, M.B., Turner, R.B., Traynor, M.J., Holt, K.B.,
`Jones, S.A. Free radical facilitated damage of ungual keratin
`(2010) Free Radical Biology and Medicine, 49 (5), pp. 865-871.
`
`Staff, K., Brown, M.B., Hider, R.C., Kong, X.L., Friden, P., Jones, S.A.
`Recovering Ga(III) from coordination complexes using pyridine 2,6-
`dicarboxylic acid chelation ion chromatography
`(2010) Biomedical Chromatography, 24 (9), pp. 1015-1022.
`
`Fiala, S., Jones, S.A., Brown, M.B. A fundamental investigation into
`the effects of eutectic formation on transmembrane transport
`(2010) International Journal of Pharmaceutics, 393 (1-2), pp. 68-73.
`
`Zhao, Y., Brown, M.B., Jones, S.A. Pharmaceutical foams: are they
`the answer to the dilemma of topical nanoparticles? (2010)
`Nanomedicine: Nanotechnology, Biology, and Medicine, 6 (2), pp.
`227-236.
`
`Zhao, Y., Brown, M.B., Jones, S.A. The effects of particle properties
`on nanoparticle drug retention and release in dynamic minoxidil
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 6
`
`

`

`foams (2010) International Journal of Pharmaceutics, 383 (1-2), pp.
`277-284.
`
`Moddaresi, M., Brown, M.B., Tamburic, S., Jones, S.A. Tocopheryl
`acetate disposition in porcine and human skin when administered
`using lipid nanocarriers (2010) Journal of Pharmacy and
`Pharmacology, 62 (6), pp. 762-769.
`
`Zhao, Y., Jones, S.A., Brown, M.B. Dynamic foams in topical drug
`delivery (2010) Journal of Pharmacy and Pharmacology, 62 (6), pp.
`678-684.
`
`Zhao, Y., Brown, M.B., Jones, S.A. The topical delivery of benzoyl
`peroxide using elegant dynamic hydrofluoroalkane foams (2010)
`Journal of Pharmaceutical Sciences, 99 (3), pp. 1384-1398.
`
`Traynor, M.J., Turner, R.B., Evans, C.R.G., Khengar, R.H., Jones,
`S.A., Brown, M.B. Effect of a novel penetration enhancer on the
`ungual permeation of two antifungal agents (2010) Journal of
`Pharmacy and Pharmacology, 62 (6), pp. 730-737.
`
`Gul, M.O., Jones, S.A., Dailey, L.A., Nacer, H., Ma, Y., Sadouki, F.,
`Hider, R., Araman, A., Forbes, B. A poly(vinyl alcohol) nanoparticle
`platform for kinetic studies of inhaled particles (2009) Inhalation
`Toxicology, 21 (7), pp. 631-640.
`
`Patel, A., Jones, S.A., Ferro, A., Patel, N. Pharmaceutical salts: A
`formulation trick or a clinical conundrum? (2009) British Journal of
`Cardiology, 16 (6), pp. 281-286.
`
`Zhao, Y., Moddaresi, M., Jones, S.A., Brown, M.B. A dynamic topical
`hydrofluoroalkane foam to induce nanoparticle modification and drug
`release in situ (2009) European Journal of Pharmaceutics and
`Biopharmaceutics, 72 (3), pp. 521-528.
`
`Zhao, Y., Brown, M.B., Jones, S.A. Engineering novel topical foams
`using hydrofluroalkane emulsions stabilised with pluronic surfactants
`(2009) European Journal of Pharmaceutical Sciences, 37 (3-4), pp.
`370-377.
`
`Moddaresi, M., Tamburic, S., Williams, S., Jones, S.A., Zhao, Y.,
`Brown, M.B. Effects of lipid nanocarriers on the performance of
`topical vehicles in vivo (2009) Journal of Cosmetic Dermatology, 8
`(2), pp. 136-143.
`
`Madlova, M., Jones, S.A., Zwerschke, I., Ma, Y., Hider, R.C., Forbes,
`B. Poly(vinyl alcohol) nanoparticle stability in biological media and
`uptake in respiratory epithelial cell layers in vitro (2009) European
`Journal of Pharmaceutics and Biopharmaceutics, 72 (2), pp. 438-443.
`
`Reid, M.L., Jones, S.A., Brown, M.B. Transient drug supersaturation
`kinetics of beclomethasone dipropionate in rapidly drying films
`(2009) International Journal of Pharmaceutics, 371 (1-2), pp. 114-
`119.
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 7
`
`

`

`Brown, M.B., Khengar, R.H., Turner, R.B., Forbes, B., Traynor, M.J.,
`Evans, C.R.G., Jones, S.A. Overcoming the nail barrier: A systematic
`investigation of ungual chemical penetration enhancement
`(2009) International Journal of Pharmaceutics, 370 (1-2), pp. 61-67.
`
`Jones, S.A., Reid, M.L., Brown, M.B.
`Determining degree of saturation after application of transiently
`supersaturated metered dose aerosols for topical delivery of
`corticosteroids (2009) Journal of Pharmaceutical Sciences, 98 (2), pp.
`543-554.
`
`Fiala, S., Brown, M.B., Jones, S.A. An investigation into the influence
`of binary drug solutions upon diffusion and partition processes in
`model membranes (2008) Journal of Pharmacy and Pharmacology,
`60 (12), pp. 1615-1623.
`
`Chana, J., Forbes, B., Jones, S.A. The synthesis of high molecular
`weight partially hydrolysed poly(vinyl alcohol) grades suitable for
`nanoparticle fabrication (2008) Journal of Nanoscience and
`Nanotechnology, 8 (11), pp. 5739-5747.
`
`Reid, M.L., Brown, M.B., Jones, S.A. Manipulation of corticosteroid
`release from a transiently supersaturated topical metered dose
`aerosol using a residual miscible co-solvent
`(2008) Pharmaceutical Research, 25 (11), pp. 2573-2580.
`
`Reid, M.L., Brown, M.B., Moss, G.P., Jones, S.A.
`An investigation into solvent-membrane interactions when assessing
`drug release from organic vehicles using regenerated cellulose
`membranes (2008) Journal of Pharmacy and Pharmacology, 60 (9),
`pp. 1139-1147.
`
`Jones, S.A., Mesgarpour, S., Chana, J., Forbes, B. Preparation and
`characterisation of polymeric nanoparticles using low molecular
`weight poly(vinyl alcohol) (2008) Journal of Biomedical
`Nanotechnology, 4 (3), pp. 319-325.
`
`Buttini, F., Soltani, A., Colombo, P., Marriott, C., Jones, S.A.
`Multilayer PVA adsorption onto hydrophobic drug substrates to
`engineer drug-rich microparticles (2008) European Journal of
`Pharmaceutical Sciences, 33 (1), pp. 20-28.
`
`Buttini, F., Colombo, P., Wenger, M.P.E., Mesquida, P., Marriott, C.,
`Jones, S.A. Back to basics: The development of a simple,
`homogenous, two-component dry-powder inhaler formulation for the
`delivery of budesonide using miscible vinyl polymers
`(2008) Journal of Pharmaceutical Sciences, 97 (3), pp. 1257-1267.
`
`Khengar, R.H., Jones, S.A., Turner, R.B., Forbes, B., Brown, M.B.
`Nail swelling as a pre-formulation screen for the selection and
`optimisation of ungual penetration enhancers (2007) Pharmaceutical
`Research, 24 (12), pp. 2207-2212.
`
`Brown, M.B., Jones, S.A., He, W., Martin, G.P.
`Hyaluronan: Investigations into the mode of action of hyaluronan in
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 8
`
`

`

`topical drug delivery (2006) ACS Symposium Series, 934, pp. 141-
`153.
`
`Jones, S.A., Martin, G.P., Brown, M.B. Stabilisation of
`deoxyribonuclease in hydrofluoroalkanes using miscible vinyl
`polymers (2006) Journal of Controlled Release, 115 (1), pp. 1-8.
`
`Brown, M.B., Martin, G.P., Jones, S.A., Akomeah, F.K.
`Dermal and transdermal drug delivery systems: Current and future
`prospects (2006) Drug Delivery: Journal of Delivery and Targeting of
`Therapeutic Agents, 13 (3), pp. 175-187.
`
`Jones, S.A., Martin, G.P., Brown, M.B. Manipulation of
`beclomethasone-hydrofluoroalkane interactions using biocompatible
`macromolecules (2006) Journal of Pharmaceutical Sciences, 95 (5),
`pp. 1060-1074.
`
`Jones, S.A., Martin, G.P., Royall, P.G., Brown, M.B. Biocompatible
`polymer blends: Effects of physical processing on the molecular
`interaction of poly(vinyl alcohol) and poly(vinyl pyrrolidone)
`(2005) Journal of Applied Polymer Science, 98 (5), pp. 2290-2299.
`
`Liao, Y.-H., Brown, M.B., Jones, S.A., Nazir, T., Martin, G.P. The
`effects of polyvinyl alcohol on the in vitro stability and delivery of
`spray-dried protein particles from surfactant-free HFA 134a-based
`pressurised metered dose inhalers (2005) International Journal of
`Pharmaceutics, 304 (1-2), pp. 29-39.
`
`Liao, Y.-H., Jones, S.A., Forbes, B., Martin, G.P., Brown, M.B.
`Hyaluronan: Pharmaceutical characterization and drug delivery
`(2005) Drug Delivery: Journal of Delivery and Targeting of
`Therapeutic Agents, 12 (6), pp. 327-342.
`Jones, S.A., Martin, G.P., Brown, M.B. High-pressure aerosol
`suspensions - A novel laser diffraction particle sizing system for
`hydrofluoroalkane pressurised metered dose inhalers
`(2005) International Journal of Pharmaceutics, 302 (1-2), pp. 154-
`165.
`
`Brown, M.B., Jones, S.A. Hyaluronic acid: A unique topical vehicle for
`the localized delivery of drugs to the skin
`(2005) Journal of the European Academy of Dermatology and
`Venereology, 19 (3), pp. 308-318.
`
`Jones, S.A., Martin, G.P., Brown, M.B.
`Determination of polyvinylpyrrolidone using high-performance liquid
`chromatography (2004) Journal of Pharmaceutical and Biomedical
`Analysis, 35 (3), pp. 621-624.
`
`Jones, S.A., Brown, M., Martin, G.P. Determination of Polyvinyl
`Alcohol Using Gel Filtration Liquid Chromatography
`(2004) Chromatographia, 59 (1-2), pp. 43-46.
`
`Jones, S. Assessing the effectiveness of one-stop dispensing
`(2002) Hospital Pharmacist, 9 (8), pp. 237-239.
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 9
`
`

`

`PATENTS
`
`‘Metered dose inhalation preparations’ Y-H Liao, S. A. Jones M. B.
`Brown and G. P. Martin. (UK0226274.9). WO2004043442 (2004).
`‘Metered dose inhalation preparations of therapeutic drugs’ S. A.
`Jones, M. B. Brown and G. P. Martin.
`(UK0328630.9).
`WO2005055985 (2005).
`‘Metered dose inhalation preparations for peptides and proteins’
`S. A. Jones, M. B. Brown and G. P. Martin. (UK0328629.1).
`WO2005056037. (2006).
`‘Topical ungula formulations’ M. B. Brown, S. A. Jones, R.
`Khengar, R. Turner. WO2006131721 (2006).
`‘Topical formulations’. S. A. Jones, M. B. Brown, M. Reid.
`(UK0518769.5) WO2007031753. (2007).
`‘Topical formulations’. S. A. Jones, M. B. Brown, Y. Zhao. UK
`Patent Appl. No (0715646.6). (2007).
`Iontophoretic Delivery of
`‘Pharmaceutical Formulations for
`Gallium’. P.M. Friden, H. Kim, K. Staff, M. B. Brown and S.A. Jones.
`US patent application 4035.3007 US (2010).
` ‘Topical heat generating formulations’. S. A. Jones, M. B. Brown,
`D. Wood. UK No (1005639.8). (2010).
`
`RESEARCH
`STUDENTS
`
`6 Post-doctoral students supervised (1 current)
`30 PhD students (24 successfully completed 6 on-going; 23 passed
`within 4 years)
`42 Masters students (all passed)
`
`1. ‘Development of novel dry-powder inhaler formulations’ PhD
`Completed 2007. Second supervisor. Collaboration with the
`University of Parma
`2. ‘Investigation into the use of novel nanocarriers’ PhD Completed
`2005. Second supervisor. Collaboration with the University of Istanbul
`3. ‘Development of novel topical metered dose aerosol sprays’ PhD
`Completed 2009. First supervisor. Self-funded student from USA
`4. ‘Engineering novel hydrofluoroalkane nanofoams’ PhD Completed
`2009. First supervisor. Dorothy Hodgkin award
`5. ‘Novel topical ungula formulations’ PhD. Completed 2009. Second
`supervisor. MedPharm Funded
`6. ‘Harnessing nanotechnology for nasal drug delivery’ PhD
`Completed 2009. First supervisor. Self-funded student from Algeria
`7. ‘Novel eutectic compositions for topical drug delivery’ PhD
`Completed 2010. First supervisor. Self-funded student from Algeria
`8. ‘Delivery of inorganic agents into the skin’ PhD. Completed 2010.
`First supervisor. Funded by MedPharm Ltd
`9. ‘Novel cosmetic formulations derived from natural sources’ PhD.
`Completed 2010. Second supervisor. Collaboration with University of
`the Arts London
`10. ‘Development of a novel self-assembling thermoregulation device’
`PhD. Completed 2010. First supervisor. Funded by MedPharm Ltd
`11. ‘Novel supersaturated systems for transdermal drug delivery’ PhD
`Completed 2010. First supervisor. Self-funded student from Algeria
`12. ‘Zinc as an antimicrobial agent’ PhD Completed 2010. Second
`supervisor. Funded by GSK.
`13. ‘The development of a novel powder formulation for topical drug
`delivery’ PhD Completed 2010. Second supervisor. Funded by
`MedPharm Ltd at University of Hertfordshire
`14. ‘Poly-vinyl nanoparticles for the administration of antimicrobials to
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 10
`
`

`

`the lung’ PhD Completed 2012. First supervisor. Self-funded student
`from Algeria
`15. ‘The absorption of ion-pairs across the respiratory epithelia’ PhD
`Completed 2013. First supervisor. Funded by Medpharm Ltd KTN
`Case award
`16. ‘Mucus penetrating nanoparticles – a novel targeting strategy for
`the treatment of respiratory disease’ PhD Completed 2014. First
`supervisor. Funded by a BBSRC DTA
`17. ‘Ion-pair inclusion complexes’
`PhD Completed 2014. First
`supervisor. Collaboration with the University of Porto
`18. ‘The influence of barometric pressure changes upon membrane
`physiology and xenobiotic penetration’ PhD Completed 2015. First
`supervisor. Funded by BBSRC CASE award
`19. ‘Self-assembling nanocrystals for topical drug delivery’ PhD
`Completed 2016. First supervisor. Self-funded student from
`Singapore
`20. ‘Nanoparticle transport through mucus’ PhD Completed 2017.
`First supervisor. Self-funding student from China
`21. ‘Multifunctional self-assembling ion-pair complexes’ PhD
`Completed 2017. First supervisor. Funded by a ESPRC CASE award
`with Johnson & Johnson
`22. ‘In vitro biopharmaceutical evaluation of novel respiratory
`medicines for airway disease’ PhD Completed 2017. First supervisor.
`Funded by MRC CASE award with GSK
`23. ‘Cyclodextrin stabilized ion-pair complexes’ PhD Completed 2018.
`First supervisor. Funded by a grant from the Malaysian Government
`24. ‘Alpha-tocopherol nanomaterials for UV protection’ PhD
`Completed 2018. First supervisor. Funded by the Jordanian
`Government
`25. ‘Hypobaric pressure facilitated drug delivery into the skin’. PhD
`Completed 2019. First supervisor. Self-funded student from Iran
`26. ‘Cyclodextrin antimicrobial complexes’ PhD completed 2018.
`Second supervisor. Self-funded student from Greece
`27. ‘Pentamadine ion-pair complexes’ PhD Current. Second
`supervisor. Self-funded student from China
`28. ‘Targeting mTOR using phosphorylated vitamin D’ PhD Current
`First supervisor. Self-funded student from Japan
`29. ‘Hydrogen sulphide as a novel antifungal’ PhD Current. First
`supervisor. Self-funded student from Jordan
`30. ‘Hydrogen sulphide to reduce food spoilage’ PhD Current. First
`supervisor. BBSRC CASE award with Natures Way Foods
`
`1. Formulation V. Berlin Germany (2007) ‘Enhancing topical drug
`delivery using a novel self-assembling supersaturated patch’.
`2. Drug Delivery to the Lungs 18. Edinburgh UK (2007) ‘Novel poly
`(vinyl alcohol-vinyl acetate) nanoparticulate systems containing
`rifampicin’.
`3. University of Bath. UK (2008) ‘The use of non-polar solvents to
`enhance topical drug delivery’.
`4. University of Parma, Italy (2008) ‘Novel topical formulations’.
`5. University of Hertfordshire (2008) ‘Non-polar solvents – ideal
`vehicles for topical drug delivery?’.
`6. 11th International Inhalation Symposium: Benefits and Risks of
`Inhaled Engineered Nanoparticles in Hannover, Germany (2008)
`‘PVA nanoparticles as tools for delivery and diagositics’.
`
`INVITED TALKS
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 11
`
`

`

`7. Drug Delivery to the Lungs 19. Edinburgh UK (2008) ‘The transport
`of nanoparticle across respiratory cell lines’.
`8. Novos Medicamentos Manipulados E Novos Sistemas
`Therapeuticos. Universidade Fernando Pessoa, Portugal (2009)
`‘Novel nasal drug delivery systems’.
`9. Inhalation Drug Development ‘Excipient selection for inhaled
`formulations’. London 22nd September (2009).
`10. 12th Biennial Perspectives in Percutaneous Penetration (PPP)
`conference. ‘Dynamic Foams for topical drug delivery’ La Grande
`Motte, France, 7–10 April (2010).
`11. UKPharmSci 2010 Plenary Lecture ‘Dynamic Aerosols: Chemical
`Solutions For Drug Delivery’ Nottingham (2010)
`12. Measurement Challenges in Analysis of Topical products. ‘Topical
`pharmaceutical salts’. A JPAG symposium. Royal Pharmaceutical
`Society, London (2011).
`13. PharmSciFair III. Pharmaceutical Sciences for the Future of
`Medicines. ‘Inhaled biopharmaceutics’ Prague, Czech Republic,
`(2011).
`14. 13th Biennial Perspectives in Percutaneous Penetration (PPP)
`conference. ‘Past, Present and future applications of topical ungual
`formulations’ La Grande Motte, France, April (2012).
`15. Biotechnology Forum, University of Oran, Algeria.
`‘Biopharmaceutical products’. (2014) in French.
`16. Formulation Perspective Conference, Munich, Germany (2015).
`‘Drug Delivery Technologies that utilise nanomaterials to enhance the
`bioavailability of topical products’
`17. Skin@Bath. Bath. UK. (2017). ‘Using nanomaterials to modify
`drug deposition profiles in the skin’
`18. 13th Meeting in Pharmaceutics, Biopharmaceutics and
`Pharmaceutical Technology. Granada, Spain. (2018) ‘Topical
`hypobaric pressure: a novel means to enhance the delivery of
`nanosized drug aggregates into the skin.’
`19. 16th Biennial Perspectives in Percutaneous Penetration (PPP)
`conference. (2018). ‘Enhancing delivery into the skin via the follicular
`route using topical hypobaric pressure’. La Grande Motte, France.
`20. University of Oxford. (2019). ‘Adverse drug reactions of topical
`and systemic medicinal products on the human skin’
`21. Skin@Bath. Bath. UK. (2019). Conference session chair – Using
`the skin for biomarker extraction
`22. University of Jordan. (2019). ‘The skin, a highly versatile organ for
`the diagnosis and treatment of human disease’
`23. 17th Biennial Perspectives in Percutaneous Penetration (PPP)
`conference. (2020). ‘Extracting macromolecules out of the skin using
`hypobaric pressure’. La Grande Motte, France.
`
`Masters in Pharmacy
`Physical Pharmaceutics (Year 1) - Laboratory class leader; Lectures:
`Colloids & Gels; Colligative properties; Electrolytes.
`Formulation Analysis (Year 2) – Lectures: Dissolution
`Medicines Discovery and Development (Year 3) – Lectures:
`Experimental Design
`Gastrointestinal and Skin (Year 3) Lectures: Drug Delivery to the skin
`
`Masters in Pharmaceutical Science
`Lectures: Dissolution, Topical Drug delivery, Crystallisation, Particle
`
`TEACHING
`
`Opiant Exhibit 2200
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 12
`
`

`

`ADMIN
`
`PEER REVIEW
`
`engineering
`
`Masters in Drug Development Science / Clinical Pharmacology
`Lectures: Clinical Pharmaceutics; Drug Formulation; Inhaled and
`Nasal Drug Delivery; Solution Formulations
`Current teaching load = 117 contact hours per year
`
`Director of the MSc in Pharmaceutical Technology 2005-2009
`Director of Pharmaceutical Science Postgraduate Studies (3 MSc
`programs in the Department of Pharmacy) 2007-2009
`Chair of t